TaiMed Biologics (4147) has been selected to present its latest research on a novel CD4+ cell-targeting antibody-drug conjugate (ADC) for the treatment of HIV at ID Week 2025, a premier global conference in the field of infectious diseases. The findings will be showcased in a poster presentation.

The presentation, titled "Development of Novel CD4+ Cell Targeting Antibody-Drug Conjugates for HIV Treatment", will take place on Tuesday, October 21, 2025, from 12:15 PM to 1:30 PM (ET) at Poster Hall B4-5 in the Georgia World Congress Center, Atlanta, Georgia, USA.

TaiMed's ADC platform is designed to precisely target the CD4 receptor on HIV target cells and deliver an effective anti-HIV payload molecule. This approach aims to enhance therapeutic specificity and efficacy while minimizing side effects to healthy cells. The advancement represents a significant milestone in precision HIV therapy and demonstrates the company’s ongoing commitment to the development of next-generation biologics.

ID Week is co-organized by the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the Pediatric Infectious Diseases Society (PIDS), and the HIV Medicine Association (HIVMA). It is one of the most prominent annual conferences in the field, drawing thousands of clinical and research professionals from around the world.
TaiMed Biologics remains dedicated to advancing innovative therapies for HIV and other serious infectious diseases, striving to provide safer and more effective treatment options for patients globally through scientific innovation.